Dapagliflozin Mechanism, Therapeutic Role, and Clinical Applications in Diabetes, Heart Failure, and Kidney Disease Introduction Dapagliflozin is an oral medication classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, developed initially for the treatment of type 2 diabetes mellitus (T2DM). Its benefits, however, […]
Empagliflozin Mechanism, Clinical Applications, and Therapeutic Impact in Diabetes and Cardiovascular Disease Introduction Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor widely used in the management of type 2 diabetes mellitus (T2DM) and associated cardiovascular and renal comorbidities. Marketed under the brand […]